Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis

Hepatocellular carcinoma (HCC) has a high mortality rate and early detection of HCC is crucial for the application of effective treatment strategies. HCC is typically caused by either viral hepatitis infection or by fatty liver disease. To diagnose and treat HCC it is necessary to elucidate the underlying molecular mechanisms. As a major cause for development of HCC is fatty liver disease, we here investigated anomalies in regulation of lipid metabolism in the liver. We applied a tailored network-based approach to identify signaling hubs associated with regulation of this part of metabolism. Using transcriptomics data of HCC patients, we identified significant dysregulated expressions of lipid-regulated genes, across many different lipid metabolic pathways. Our findings, however, show that viral hepatitis causes HCC by a distinct mechanism, less likely involving lipid anomalies. Based on our analysis we suggest signaling hub genes governing overall catabolic or anabolic pathways, as novel drug targets for treatment of HCC that involves lipid anomalies.

[1]  Andreas Zell,et al.  JSBML: a flexible Java library for working with SBML , 2011, Bioinform..

[2]  G. Hong,et al.  Nucleic Acids Research , 2015, Nucleic Acids Research.

[3]  M. Stoffel,et al.  Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes , 2004, Nature.

[4]  Gábor Csárdi,et al.  The igraph software package for complex network research , 2006 .

[5]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[6]  Simo V. Zhang,et al.  A map of human cancer signaling , 2007, Molecular systems biology.

[7]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[8]  Sahil Mittal,et al.  Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.

[9]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[10]  Doheon Lee,et al.  Anomalies in Network Bridges Involved in Bile Acid Metabolism Predict Outcomes of Colorectal Cancer Patients , 2014, PloS one.

[11]  Z. Bar-Joseph,et al.  Linking the signaling cascades and dynamic regulatory networks controlling stress responses , 2013, Genome research.

[12]  Michael G. Rosenfeld,et al.  Controlling nuclear receptors: the circular logic of cofactor cycles , 2005, Nature Reviews Molecular Cell Biology.

[13]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[14]  Gary D. Bader,et al.  Using Biological Pathway Data with Paxtools , 2013, PLoS Comput. Biol..

[15]  W. Wahli,et al.  Sex differences in nuclear receptor-regulated liver metabolic pathways. , 2011, Biochimica et biophysica acta.

[16]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[17]  Margaret S. Wu,et al.  Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes , 2011, Proceedings of the National Academy of Sciences.

[18]  A. Diehl,et al.  NAFLD, NASH and liver cancer , 2013, Nature Reviews Gastroenterology &Hepatology.

[19]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[20]  M. Sani,et al.  Lipid-lowering drugs. , 2004, Nursing older people.

[21]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[22]  H. M. Reis,et al.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma , 2013, Nature Reviews Cancer.

[23]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[24]  Martin Kuiper,et al.  BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..

[25]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[27]  K. Tsai,et al.  TAp63 is a master transcriptional regulator of lipid and glucose metabolism. , 2012, Cell metabolism.

[28]  Karin Dahlman-Wright,et al.  Liver X receptor in cholesterol metabolism. , 2010, Journal of Endocrinology.

[29]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.

[30]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  I. Nookaew,et al.  Integration of clinical data with a genome-scale metabolic model of the human adipocyte , 2013, Molecular systems biology.

[32]  J. Pekow,et al.  Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C‐related cirrhosis , 2007, Cancer.

[33]  M. Murad,et al.  Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. , 2013, Gastroenterology.

[34]  Guido Gerken,et al.  The interaction of hepatic lipid and glucose metabolism in liver diseases. , 2012, Journal of hepatology.

[35]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[36]  Peter Tontonoz,et al.  Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.

[37]  Johan Auwerx,et al.  Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.

[38]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[39]  M. Stoffel,et al.  Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion. , 2006, Cell metabolism.

[40]  Anushya Muruganujan,et al.  PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees , 2012, Nucleic Acids Res..

[41]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[42]  Hans-Werner Mewes,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[43]  M. Uhlén,et al.  Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[44]  D. Calvisi,et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.

[45]  A. Dobrzyń,et al.  Stearoyl‐CoA desaturase as a new drug target for obesity treatment , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[46]  Réka Albert,et al.  Elementary signaling modes predict the essentiality of signal transduction network components , 2011, BMC Systems Biology.

[47]  Jerrold M. Ward,et al.  Hepatocyte Nuclear Factor 4α (Nuclear Receptor 2A1) Is Essential for Maintenance of Hepatic Gene Expression and Lipid Homeostasis , 2001, Molecular and Cellular Biology.

[48]  Gary D Bader,et al.  BioPAX – A community standard for pathway data sharing , 2010, Nature Biotechnology.

[49]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[50]  Peng Qiu,et al.  TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.

[51]  David B. Berry,et al.  Pathway connectivity and signaling coordination in the yeast stress-activated signaling network , 2014, Molecular systems biology.

[52]  J. Dufour,et al.  Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. , 2011, Cancer research.

[53]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[54]  H. J. Lin,et al.  The ether lipid tumour marker in human liver with hepatocellular carcinoma. , 1980, British Journal of Cancer.

[55]  C. Byrne Fatty liver: role of inflammation and fatty acid nutrition. , 2010, Prostaglandins, leukotrienes, and essential fatty acids.

[56]  O. Boss,et al.  GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. , 2004, The Journal of clinical investigation.

[57]  Damian Smedley,et al.  The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data , 2014, Nucleic Acids Res..

[58]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[59]  F. Basile,et al.  Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma , 2011, Indian Journal of Medical and Paediatric Oncology.

[60]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[61]  W. Wahli,et al.  PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.